MONDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 09/10/20
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)PRNewsWire • 09/09/20
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 09/09/20
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/09/20
Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Verrica Pharmaceuticals Inc. To Contact The FirmNewsfile Corp • 09/08/20
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 09/08/20
VRCA Class Action Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the FirmNewsfile Corp • 08/25/20
Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology IndicationsGlobeNewsWire • 08/11/20
Verrica Pharmaceuticals: The Fundamentals Aren't So Clear, But The Stock Chart May Be Telling Us SomethingSeeking Alpha • 07/30/20
VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the FirmNewsfile Corp • 07/24/20
Verrica Pharmaceuticals Announces Dr. Lawrence Eichenfield Joins Board of DirectorsGlobeNewsWire • 07/23/20
Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership ChangesGlobeNewsWire • 07/23/20
VRCA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the FirmNewsfile Corp • 07/22/20
Verrica Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Verrica Pharmaceuticals Inc. To Contact The FirmNewsfile Corp • 07/20/20
Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Verrica Pharmaceuticals, Inc. – VRCABusiness Wire • 07/17/20
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 07/17/20
Shareholder Alert: Robbins LLP Announces Verrica Pharmaceuticals Inc. (VRCA) Accused of Misleading ShareholdersBusiness Wire • 07/16/20
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 07/16/20
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 07/16/20
VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the FirmNewsfile Corp • 07/15/20
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals Inc.Business Wire • 07/15/20
VERRICA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc.Business Wire • 07/14/20
The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc.Business Wire • 07/14/20
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumGlobeNewsWire • 07/14/20